Earnings analysis · 10-K
QNME earnings analysis
Filed September 25, 2026 · Our reading of the company's report
The latest report
Quanome’s continuing pharmaceutical business showed strong early growth, with revenue up 111.8% to $5.85 million and gross margin improving to 56.7%, while the disposal of ABL Chicago removed a loss-making logistics…
Read full summary
Quanome’s continuing pharmaceutical business showed strong early growth, with revenue up 111.8% to $5.85 million and gross margin improving to 56.7%, while the disposal of ABL Chicago removed a loss-making logistics operation. However, operating expenses, a $2.86 million supplier-advance write-off and a $2.26 million loan-credit-loss provision drove a $10.14 million continuing-operations loss and $3.18 million of operating cash burn. The new AI infrastructure strategy is potentially transformative but remains pre-revenue and is paired with an approximately $18.8 million GPU commitment, while the going-concern qualification, material control weaknesses and Nasdaq compliance issue materially constrain the outlook.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
Reported figures
- Earnings per share
- $-0.36
What stood out
-
Pharma revenue more than doubled
Pharmaceutical distribution revenue increased 111.8% to $5,850,681 in FY2026 from $2,762,465 in FY2025, driven by higher infusion-product sales, active customers increasing from 8 to 12, and a full year of operations.
-
Gross margin expanded modestly
Gross profit rose 113.9% to $3,315,042, while gross margin improved to 56.7% from 56.1%, primarily due to increased supplier purchase rebates.
-
Infusion products drive growth
Infusion products accounted for 91.1% of pharmaceutical distribution revenue in FY2026, up from 82.9% in FY2025; infusion-product revenue increased approximately $3.0 million to $5.3 million.
-
Exited loss-making logistics business
The company completed the strategic disposal of ABL Chicago effective February 12, 2026, recording a $2,556,315 gain and eliminating the prior logistics business’s $3,468,721 FY2025 operating loss from continuing operations.
-
External financing supported liquidity
Financing provided $7,767,642 of cash in FY2026, including $8,236,231 from private placements, partly offset by $432,948 of convertible-debt principal repayments; convertible debt outstanding was subsequently repaid in full.
-
New AI infrastructure strategy launched
The company began AI compute and managed-inference activities in September 2026 through XDT Infrastructure; the filing states that it does not plan to develop or train proprietary AI models and instead provides customer-accessible computing infrastructure.
What to watch
-
Going-concern and funding risk
The company reported substantial doubt about going concern: FY2026 net loss from continuing operations was approximately $10.1 million, operating cash use was approximately $3.2 million, accumulated deficit was approximately $14.8 million, and cash was only approximately $0.7 million at June 30, 2026. Management states continued operations depend on external financing and that there is no assurance sufficient funds will be secured.
-
Material concentration in loan receivable
A third-party loan had a gross balance of $9,437,984 and a $2,256,647 credit-loss allowance at June 30, 2026; the $7,181,337 net balance represented 65.2% of total current assets. The company states that default or delayed repayment could impair liquidity and require alternative financing.
-
Unproven AI business and GPU commitment
The AI compute business had no revenue and no customers as of the annual-report date, while specialized infrastructure may require significant expenditures before meaningful recurring revenue. Separately, the company committed to purchase 32 GPU server units for approximately $18.8 million, with 20% due after order acceptance and the remaining 80% due before shipment.
-
Material weaknesses in financial controls
Management concluded internal control over financial reporting was not effective as of June 30, 2026 due to inadequate segregation of duties and risk assessment and insufficient written U.S. GAAP and SEC reporting policies. Remediation remains ongoing, creating risk of untimely or inaccurate reporting.
-
Customer and supplier concentration
The company depends heavily on a concentrated pharmaceutical ecosystem: four customers represented 22.0%, 16.4%, 12.6% and 12.6% of FY2026 revenue, while two suppliers represented 49.7% and 40.0% of total purchases.
-
Nasdaq minimum-bid compliance risk
Nasdaq granted the company until January 4, 2027 to regain compliance after its stock remained below the $1.00 minimum bid price for 30 consecutive business days. The company may need a reverse stock split, and delisting could impair liquidity and access to capital.
Management's outlook
No quantitative revenue or EPS guidance is provided in the 10-K. Management states that capital expenditures are expected to increase as the business develops and expands, with future spending expected to be funded through cash, loans, convertible debt and private placements.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.